Allarity Q1 net loss $3.8M; Phase 2 stenoparib benefit, equity $15M, Nasdaq compliance

Allarity Therapeutics, Inc.

2024-Q1 EPS reported -$22.14

Phase 2 stenoparib trial concluded early due to clear clinical benefits: tumor shrinkage and long-term disease stability in ovarian cancer; preparing follow-on trial with FDA intent.
Cash balance $14M, stockholders' equity $15M, exceeding Nasdaq $2.5M minimum; seeking formal compliance confirmation.
Net loss $3.8M for Q1 2024 vs $3.4M Q1 2023; R&D expenses $2.2M (+$0.7M YoY), G&A $2.1M (flat).
Regained Nasdaq bid price compliance after reverse stock split; capital structure simplified: all variable-priced warrants exercised, Series A Preferred converted.
Withdrew Form S-1 registration; focus solely on stenoparib, deprioritizing IXEMPRA and dovitinib.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allarity Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income -$3.8 million.

Period: first quarter ended March 31, 2024
Net income: -$3.8 million
Result: reported results

Exact text from the filing

Net loss was $3.8 million for the quarter ended March 31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-043238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.